TERAPAVE® AEA admixture is an aqueous solution of a complex mixture of organic acid salts. TERAPAVE® AEA is specially formulated for use as an air-entraining admixture for concrete paving and provides uniform, predictable performance. It is supplied ready-to-use and does not require premixing with water. TERAPAVE® AEA conforms to ASTM C260. One gallon weighs approximately 8.5 lbs (1.02 kg/L).
TERAPAVE® AEA is used in low slump concrete, particularly for highway paving applications, where concrete is mixed and there is a need for purposeful air entrainment.
Air is entrained by the development of a semi-microscopic bubble system—introduced into the mix by agitation and stabilized by TERAPAVE® AEA—in the mortar phase of the concrete.
TERAPAVE® AEA concrete is extremely durable, particularly when subjected to freezing, thawing and deicing salts.
There is no standard addition rate for TERAPAVE® AEA. The amount to be used will depend upon the amount of air required under job conditions, usually in the range of 4% to 8%. Typical factors that might influence the amount of air entrained are: temperature, cement, sand gradation and use of extra fine materials such as fly ash. Typical TERAPAVE® AEA addition rates range from ½ to 3 fl oz/100 lbs (30 to 200 mL/100 kg) of cement.
The air-entraining efficiency of TERAPAVE® AEA becomes even greater when used with water-reducing and set-retarding agents. This may allow a reduction of up to two-thirds in the amount of TERAPAVE® AEA required for the specified air content.
Entrained air will increase the volume of the concrete, making it necessary to adjust the mix proportions to maintain the cement factor and yield. This may be accomplished by a reduction in water requirement and aggregate content.
TERAPAVE® AEA is available in bulk, delivered in metered tank trucks, totes and drums.
TERAPAVE® AEA freezes at about 30 °F (-1 °C), but its air-entraining properties are completely restored by thawing and thorough mechanical agitation.
A complete line of automatic TERAPAVE® AEA dispensers is available. Accurate and simple, these dispensers are easily adapted to existing facilities on paving mixers and in batching plants.
TERAPAVE® AEA is compatible with most GCP admixtures as long as they are added separately to the concrete mix. In general, it is recommended that TERAPAVE® AEA be added to the concrete mix near the beginning of the batch sequence for optimum performance, preferably by “dribbling” on the sand. Different sequencing may be used if local testing shows better performance. Please see GCP Technical Bulletin TB-0110, Admixture Dispenser Discharge Line Location and Sequencing for Concrete Batching Operations for further recommendations. TERAPAVE® AEA should not come in contact with any other admixture before or during the batching process, even if diluted in mix water. TERAPAVE® AEA should not be added directly to heated water.
Pretesting of the concrete mix should be performed before use, as conditions and materials change in order to assure compatibility, and to optimize dosage rates, addition times in the batch sequencing and concrete performance. Please consult your GCP Applied Technologies representative for guidance.
Concrete shall be air entrained concrete, containing 4% to 8% entrained air. The air contents in the concrete shall be determined by the pressure method (ASTM Designation C231), volumetric method (ASTM Designation C173) or gravimetric method (ASTM Designation C138). The air-entraining admixture shall be TERAPAVE® AEA, as manufactured by GCP Applied Technologies, or equal. The air-entraining admixture shall be added at the concrete mixer or batching plant in such quantities as to give the specified air contents.
We hope the information here will be helpful. It is based on data and knowledge considered to be true and accurate, and is offered for consideration, investigation and verification by the user, but we do not warrant the results to be obtained. Please read all statements, recommendations, and suggestions in conjunction with our conditions of sale, which apply to all goods supplied by us. No statement, recommendation, or suggestion is intended for any use that would infringe any patent, copyright, or other third party right.
TERAPAVE is a trademark, which may be registered in the United States and/or other countries, of GCP Applied Technologies Inc. This trademark list has been compiled using available published information as of the publication date and may not accurately reflect current trademark ownership or status.
© Copyright 2019 GCP Applied Technologies Inc. All rights reserved.
GCP Applied Technologies Inc., 2325 Lakeview Parkway, Suite 475, Alpharetta, GA 30009, USA
GCP Canada, Inc., 294 Clements Road, West, Ajax, Ontario, Canada L1S 3C6.
This document is only current as of the last updated date stated below and is valid only for use in the Canada. It is important that you always refer to the currently available information at the URL below to provide the most current product information at the time of use. Additional literature such as Contractor Manuals, Technical Bulletins, Detail Drawings and detailing recommendations and other relevant documents are also available on www.gcpat.com. Information found on other websites must not be relied upon, as they may not be up-to-date or applicable to the conditions in your location and we do not accept any responsibility for their content. If there are any conflicts or if you need more information, please contact GCP Customer Service.
Last Updated: 2024-06-21
https://ca.gcpat.com/en/solutions/products/terapave-aea